Supply & License Agreement for First-Ever Point of Care Vet Cancer Screen
![HSKA billboard in the city](https://www.marshallip.com/content/uploads/2022/06/HSKA_032922_VNRX-default-case-study-photo-10883-1-default-case-study-photo-10883.jpg)
Marshall Gerstein represented Volition Rx Limited in an exclusive global supply and licensing agreement with Heska Corporation to sell Volition’s Nu.Q® Vet Cancer Test. The transaction clears the way for the first cancer screening available at clinics and other points of care, opening a market for cancer screening and monitoring for dogs and cats estimated to be worth more than $11 billion. The $28 million transaction--$10 million upfront and up to $18 million based upon achieving near/mid-term milestones—advances Volition’s strategy to ensure the broadest possible accessibility to the Nu.Q® Test worldwide. Volition continues to make significant progress in ongoing negotiations with the multi-national veterinary companies to provide central lab global coverage for the Nu.Q® Test. The firm is also negotiating these strategic partnerships.